During the TEMPO trial patients with CKD function 1,2 and 3 were enrolled and found to benefit from tolvaptan, that is less kidney enlargment and less deterioration of renal function(as compared to placebo). There were no stage 4 patients, therefore the benefit here is not demonstrated but is presently being tested in an ongoing study (REPRISE).